Furthermore, the tumor weight did not differ significantly between the combination group and sunitinib group (P=0.409), indicating the potent tumor control upon combination treatment with the PDPK1 inhibitor and autophagy inhibitor (Fig. 5C-E). Here, PDPK1 is linked to neoplasm.